{
    "nct_id": "NCT04382326",
    "official_title": "A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS",
    "inclusion_criteria": "* Male or female infants born at >36 weeks of gestation and 2 months of age at the time of consent.\n* Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.\nHealthy volunteers allowed\nMust have minimum age of 42 Days\nMust have maximum age of 98 Days",
    "exclusion_criteria": "* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)\n* Major known congenital malformation or serious chronic disorder\n* Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results\n* Previous receipt of >1 dose of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at >30 days old, or previous receipt of any licensed or investigational pneumococcal vaccine, or planned receipt through study participation",
    "miscellaneous_criteria": ""
}